Prasugrel (CS-747) achieves significantly higher inhibition of platelet aggregation and a lower rate of nonresponders compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease

被引：0
|
作者：
Winters, KJ
Jernberg, T
Leese, PT
Nilsson, LG
Payne, CD
Darstein, C
Brandt, JT
Jakubowski, JA
Siegbahn, A
Wallentin, L
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Uppsala Hosp, Uppsala, Sweden
[3] Quintiles Phase I Serv, Lenexa, KS USA
[4] Quintiles AB Phase I Serv, Uppsala, Sweden
[5] Eli Lilly & Co, Windlesham, Surrey, England
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2005年 / 96卷 / 7A期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：154H / 154H
页数：1
相关论文
共 14 条
  • [1] Inhibition of platelet aggregation with prasugrel (CS-747, LY640315), a novel thanopyridine P2Y12 receptor antagonist, compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease
    Wallentin, L
    Jernberg, T
    Leese, PT
    Nilsson, LG
    Payne, CD
    Darstein, C
    Brandt, JT
    Jakubowski, JA
    Winters, KJ
    Siegbahn, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 416A - 416A
  • [2] Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    Jernberg, T
    Payne, CD
    Winters, KJ
    Darstein, C
    Brandt, JT
    Jakubowski, JA
    Naganuma, H
    Siegbahn, A
    Wallentin, L
    EUROPEAN HEART JOURNAL, 2006, 27 (10) : 1166 - 1173
  • [3] Prasugrel (CS-747), a novel thienopyridine P2Y12 receptor antagonist, results in more effective platelet inhibition than clopidogrel in aspirin-treated patients with atherosclerotic disease
    Wallentin, L. C.
    Jernberg, T.
    Leese, P. T.
    Siegbahn, A.
    Naganuma, H.
    Payne, C.
    Darstein, C.
    Winters, K. J.
    EUROPEAN HEART JOURNAL, 2005, 26 : 488 - 488
  • [4] Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study
    Serebruany, V. L.
    Midei, M. G.
    Meilman, H.
    Malinin, A. I.
    Lowry, D. R.
    POSTGRADUATE MEDICAL JOURNAL, 2006, 82 (968) : 404 - 410
  • [5] Platelet inhibition with prasugrel (CS-747) versus clopidogrel in patients undergoing coronary stenting (JUMBO platelet substudy)
    Serebruany, V.
    Midei, M.
    Meilman, H.
    Malinin, A.
    Lowry, D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 393 - 393
  • [6] Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
    Payne, Christopher D.
    Li, Ying G.
    Brandt, John T.
    Jakubowski, Joseph A.
    Small, David S.
    Farid, Nagy A.
    Salazar, Daniel E.
    Winters, Kenneth J.
    PLATELETS, 2008, 19 (04) : 275 - 281
  • [7] Greater inhibition of platelet aggregation with a prasugrel 60 mg loading dose compared with a clopidogrel 600 mg loading dose in aspirin-treated patients
    Varenhorst, C.
    Braun, O.
    James, S.
    Erlinge, D.
    Winters, K. J.
    Brandt, J. T.
    Jakubowski, J. A.
    Costigan, T.
    Siegbahn, A.
    Wallentin, L. C.
    EUROPEAN HEART JOURNAL, 2007, 28 : 189 - 189
  • [8] Platelet inhibition and pharmacokinetics following prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 receptor antagonist, or clopidogrel in healthy, aspirin-treated subjects
    Payne, C. D.
    Jakubowski, J. A.
    Brandt, J. T.
    Weerakkody, G. J.
    Jansen, M.
    Naganuma, H.
    Winters, K. J.
    EUROPEAN HEART JOURNAL, 2005, 26 : 584 - 584
  • [9] Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel
    Brandt, JT
    Payne, CD
    Weerakkody, G
    Behounek, BD
    Naganuma, H
    Jakubowski, JA
    Wiviott, SD
    Winters, KJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 87A - 87A
  • [10] Platelet inhibition with prasugrel (CS-747) versus clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO trial
    Serebruany, Victor L.
    Midei, Mark
    Meilman, Henry
    Malinin, Alex
    Lowry, David
    CIRCULATION, 2006, 114 (18) : 813 - 814
12